These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 18452460

  • 1. Neuroendocrine differentiation in stage D2 prostate cancers.
    Kamiya N, Suzuki H, Kawamura K, Imamoto T, Naya Y, Tochigi N, Kakuta Y, Yamaguchi K, Ishikura H, Ichikawa T.
    Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Neuroendocrine differentiation in colorectal carcinomas.
    Syversen U, Halvorsen T, Mårvik R, Waldum HL.
    Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):667-74. PubMed ID: 8590163
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
    Theodoropoulos VE, Tsigka A, Mihalopoulou A, Tsoukala V, Lazaris AC, Patsouris E, Ghikonti I.
    Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma.
    Sciarra A, Di Silverio F, Autran AM, Salciccia S, Gentilucci A, Alfarone A, Gentile V.
    Urol Int; 2009 Oct; 82(2):147-51. PubMed ID: 19321999
    [Abstract] [Full Text] [Related]

  • 7. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients.
    Sasaki T, Komiya A, Suzuki H, Shimbo M, Ueda T, Akakura K, Ichikawa T.
    Eur Urol; 2005 Aug; 48(2):224-9; discussion 229-30. PubMed ID: 16005374
    [Abstract] [Full Text] [Related]

  • 8. Secretagogin is a new neuroendocrine marker in the human prostate.
    Adolf K, Wagner L, Bergh A, Stattin P, Ottosen P, Borre M, Birkenkamp-Demtröder K, Orntoft TF, Tørring N.
    Prostate; 2007 Apr 01; 67(5):472-84. PubMed ID: 17285592
    [Abstract] [Full Text] [Related]

  • 9. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
    Sciarra A, Di Silverio F.
    Urology; 2004 Mar 01; 63(3):523-7. PubMed ID: 15028450
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
    Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, Russo L, Cracco C, Bollito E, Scarpa RM, Angeli A, Dogliotti L.
    Endocr Relat Cancer; 2005 Mar 01; 12(1):109-17. PubMed ID: 15788643
    [Abstract] [Full Text] [Related]

  • 12. Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients.
    Yashi M, Muraishi O, Kobayashi Y, Tokue A, Nanjo H.
    Prostate; 2002 May 01; 51(2):84-97. PubMed ID: 11948963
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Immunohistochemical study of chromogranin A in Stage D2 prostate cancer.
    Kokubo H, Yamada Y, Nishio Y, Fukatsu H, Honda N, Nakagawa A, Saga S, Tsuzuki T, Hara K.
    Urology; 2005 Jul 01; 66(1):135-40. PubMed ID: 15992907
    [Abstract] [Full Text] [Related]

  • 17. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer.
    Puccetti L, Supuran CT, Fasolo PP, Conti E, Sebastiani G, Lacquaniti S, Mandras R, Milazzo MG, Dogliani N, De Giuli P, Fasolis G.
    Eur Urol; 2005 Aug 01; 48(2):215-21; Discussion 221-3. PubMed ID: 15992991
    [Abstract] [Full Text] [Related]

  • 18. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
    Alessandro S, Vincenzo G, Maria AG, Stefano S, Alessandro G, Salvatore M, Vincenzo T, Franco DS.
    Endocr Relat Cancer; 2007 Sep 01; 14(3):625-32. PubMed ID: 17914093
    [Abstract] [Full Text] [Related]

  • 19. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer.
    Gregorc V, Spreafico A, Floriani I, Colombo B, Ludovini V, Pistola L, Bellezza G, Viganò MG, Villa E, Corti A.
    Cancer; 2007 Aug 15; 110(4):845-53. PubMed ID: 17599769
    [Abstract] [Full Text] [Related]

  • 20. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?
    Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjølnerød OK, Waldum HL.
    Prostate; 1997 Jan 01; 30(1):1-6. PubMed ID: 9018329
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.